Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial (ROSETTA Gastric-204) is evaluating Pumitamig plus chemotherapy versus Nivolumab plus chemotherapy as first-line treatment for untrea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Pumitamig
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Phase 2, Phase 3 | Status: RECRUITING